| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000022619 |
| Receipt No. | R000026007 |
| Scientific Title | Exploratory study on breast reconstruction method after breast-conserving surgery with autologous stem cell-mixed free fat transplantation. |
| Date of disclosure of the study information | 2016/07/01 |
| Last modified on | 2020/12/09 (Ver. 3) |
| Basic information | ||
| Public title | Exploratory study on breast reconstruction method after breast-conserving surgery with autologous stem cell-mixed free fat transplantation. | |
| Acronym | Breast reconstruction by adipose-derived stem cell-mixed free fat transplantation. | |
| Scientific Title | Exploratory study on breast reconstruction method after breast-conserving surgery with autologous stem cell-mixed free fat transplantation. | |
| Scientific Title:Acronym | Breast reconstruction by adipose-derived stem cell-mixed free fat transplantation. | |
| Region |
|
|
| Condition | ||
| Condition | Patients with breast deformation following breast-conserving surgery | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Evaluation of the clinical effect and safety of an adipose tissue-regenerative treatment, autologous adipose derived stem cell-mixed free fat transplantation, for breast deformation following surgery for breast cancer |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Quantitative analysis of breast soft tissue: Decreased amounts at postoperative weeks 4 vs. 16 |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Historical |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | In the operating room, adipose-derived stem cells were separated from the patient's fat tissue using Icellator Cell Isolation System and its accompanying enzyme, adipase. Fat for transplantation was mixed with the adipose derived stem cells to be injected into the recessed area of the breast. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | 1) One or more years after breast-conserving surgery
2) The clinical stage at the time of the above 1) breast-conserving surgery is T1N0M0 early breast cancer (ipsilateral multiple and bilateral breast cancers are ineligible) (refer to the breast cancer stage classification). Regarding the histology of breast cancer, 1% or more cells are estrogen receptor-positive and HER2 meets one of the following conditions: Tumor cells in a tissue sample of the primary lesion are (-) or (+) on immunohistological staining (IHC) . Tumor cells in a tissue sample of the primary lesion are (2+) on IHC and FISH-negative. 3) Female 4) Age from 20 to 79 years old at the time of registration 5) Written informed consent from the patient |
|||
| Key exclusion criteria | 1) Past medical history of ipsilateral multiple or bilateral breast cancers
2) Synchronous double cancer or metachronous cancer diagnosed within 5 years (appropriately treated carcinoma in situ and superficial bladder carcinoma and endoscopically curable malignant tumors are eligible) 3) Past medical history of anticancer drug administration for breast cancer 4) Infection of the breast for which transplantation is planned and the abdominal region from which fat will be collected 5) Local recurrence of breast cancer, distant metastasis, and double cancer 6) Active infection 7) Serious complications (heart, lung, liver, and kidney diseases, hemorrhagic tendency, and uncontrollable diabetes and hypertension) 8) Treatment with oral anticoagulants and antiplatelet agents 9) Pregnant and lactating women and possibly pregnant women 10) Alcohol or drug dependence within the past 6 months 11) Being judged as ineligible by the physician in charge of the study |
|||
| Target sample size | 5 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Kansai Medical University | ||||||
| Division name | Department of Plastic and Reconstructive Surgery | ||||||
| Zip code | |||||||
| Address | 2-5-1, Shinmachi, Hirakata city, 573-1010, Japan | ||||||
| TEL | 072-804-0101 | ||||||
| kusumoto@hirakata.kmu.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Kansai Medical University | ||||||
| Division name | Department of Plastic and Reconstructive Surgery | ||||||
| Zip code | |||||||
| Address | 2-5-1, Shinmachi, Hirakata city, 573-1010, Japan | ||||||
| TEL | 072-804-0101 | ||||||
| Homepage URL | |||||||
| kakudon@hirakata.kmu.ac.jp | |||||||
| Sponsor | |
| Institute | Kansai Medical University
|
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kansai Medical University |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000026007 |